Epigenetic modification and BRAF gene mutation in thyroid carcinoma

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Thyroid cancer remains the most prevailing endocrine malignancy, and a progressively increasing incidence rate has been observed in recent years, with 95% of thyroid cancer represented by differentiated thyroid carcinomas. The genetics and epigenetics of thyroid cancer are gradually increasing, and gene mutations and methylation changes play an important roles in its occurrence and development. Although the role of RAS and BRAF mutations in thyroid cancer have been partially clarified,but the pathogenesis and molecular mechanisms of thyroid cancer remain to be elucidated. Epigenetic modification refer to genetic modification that does not change the DNA sequence of a gene but causes heritable phenotypic changes in its expression. Epigenetic modification mainly includes four aspects: DNA methylation, chromatin remodelling, noncoding RNA regulation, and histone modification. This article reviews the importance of thyroid cancer epigenetic modification and BRAF gene mutation in the treatment of thyroid cancer.

Related collections

Most cited references 131

Record: found
Abstract: found
Article: not found

Cancer statistics, 2019

Rebecca Siegel, Kimberly D Miller, Ahmedin Jemal (2019)

Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States and compiles the most recent data on cancer incidence, mortality, and survival. Incidence data, available through 2015, were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data, available through 2016, were collected by the National Center for Health Statistics. In 2019, 1,762,450 new cancer cases and 606,880 cancer deaths are projected to occur in the United States. Over the past decade of data, the cancer incidence rate (2006-2015) was stable in women and declined by approximately 2% per year in men, whereas the cancer death rate (2007-2016) declined annually by 1.4% and 1.8%, respectively. The overall cancer death rate dropped continuously from 1991 to 2016 by a total of 27%, translating into approximately 2,629,200 fewer cancer deaths than would have been expected if death rates had remained at their peak. Although the racial gap in cancer mortality is slowly narrowing, socioeconomic inequalities are widening, with the most notable gaps for the most preventable cancers. For example, compared with the most affluent counties, mortality rates in the poorest counties were 2-fold higher for cervical cancer and 40% higher for male lung and liver cancers during 2012-2016. Some states are home to both the wealthiest and the poorest counties, suggesting the opportunity for more equitable dissemination of effective cancer prevention, early detection, and treatment strategies. A broader application of existing cancer control knowledge with an emphasis on disadvantaged groups would undoubtedly accelerate progress against cancer.

0 comments Cited 7076 times – based on 0 reviews      Review now

Record: found
Abstract: found
Article: found

Is Open Access

Role of TET enzymes in DNA methylation, development, and cancer

Kasper Rasmussen, Kristian Helin (2016)

Ten eleven translocation (TET) genes, and especially TET2, are frequently mutated in various cancers, but how the TET proteins contribute to the onset and maintenance of these malignancies is largely unknown. In this review, Rasmussen and Helin highlight recent advances in understanding the physiological function of the TET proteins and their role in regulating DNA methylation and transcription. The pattern of DNA methylation at cytosine bases in the genome is tightly linked to gene expression, and DNA methylation abnormalities are often observed in diseases. The ten eleven translocation (TET) enzymes oxidize 5-methylcytosines (5mCs) and promote locus-specific reversal of DNA methylation. TET genes, and especially TET2 , are frequently mutated in various cancers, but how the TET proteins contribute to prevent the onset and maintenance of these malignancies is largely unknown. Here, we highlight recent advances in understanding the physiological function of the TET proteins and their role in regulating DNA methylation and transcription. In addition, we discuss some of the key outstanding questions in the field.

0 comments Cited 469 times – based on 0 reviews      Review now

Record: found
Abstract: found
Article: not found

A decade of exploring the cancer epigenome - biological and translational implications.

Stephen Baylin, Peter A. Jones (2011)

The past decade has highlighted the central role of epigenetic processes in cancer causation, progression and treatment. Next-generation sequencing is providing a window for visualizing the human epigenome and how it is altered in cancer. This view provides many surprises, including linking epigenetic abnormalities to mutations in genes that control DNA methylation, the packaging and the function of DNA in chromatin, and metabolism. Epigenetic alterations are leading candidates for the development of specific markers for cancer detection, diagnosis and prognosis. The enzymatic processes that control the epigenome present new opportunities for deriving therapeutic strategies designed to reverse transcriptional abnormalities that are inherent to the cancer epigenome.

0 comments Cited 415 times – based on 0 reviews      Review now

All references

Author and article information

Contributors

Jiliang Xia: jiliang-xia@usc.edu.cn

Xi Zeng:

ORCID: http://orcid.org/0000-0001-6835-9691

xzeng@usc.edu.cn

Journal

Journal ID (nlm-ta): Cancer Cell Int

Journal ID (iso-abbrev): Cancer Cell Int

Title: Cancer Cell International

Publisher: BioMed Central (London )

ISSN (Electronic): 1475-2867

Publication date (Electronic): 19 December 2021

Publication date PMC-release: 19 December 2021

Publication date Collection: 2021

Volume: 21

Electronic Location Identifier: 687

Affiliations

[1 ]GRID grid.412017.1, ISNI 0000 0001 0266 8918, Hengyang Medical College, , University of South China, ; Hengyang, 421001 Hunan China

[2 ]GRID grid.412017.1, ISNI 0000 0001 0266 8918, Key Laboratory of Tumor Cellular and Molecular Pathology, , College of Hunan Province, Cancer Research Institute, University of South China, ; Hengyang, 421001 Hunan China

[3 ]GRID grid.412017.1, ISNI 0000 0001 0266 8918, Department of Radiotherapy, , The Second Affiliated Hospital, Hengyang Medical College, University of South China, ; Hengyang, 421001 Hunan China

Author information

Xi Zeng http://orcid.org/0000-0001-6835-9691

Article

Publisher ID: 2405

DOI: 10.1186/s12935-021-02405-w

PMC ID: 8684614

PubMed ID: 34923978

SO-VID: 126fe92b-5163-4834-8521-9b9a112ce300

License:

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

History

Date received : 20 October 2021

Date accepted : 9 December 2021

Custom metadata

ScienceOpen disciplines: Oncology & Radiotherapy

Keywords: thyroid carcinoma,epigenetics,braf,treatment

Data availability:

ScienceOpen disciplines: Oncology & Radiotherapy

Keywords: thyroid carcinoma, epigenetics, braf, treatment

Comments

Comment on this article

Cited by 14

See all cited by

Most referenced authors 2,250

See all reference authors